The project
The liver and the gastrointestinal (GI) tract are closely linked. Therefore it is not surprising that an imbalance of the GI microbiome is associated with all stages of NAFLD as shown recently. BestTreat aims to disentangle the mechanistic basis of the complex interactions of microbiota, host metabolism and NAFLD by integrating emerging technologies in medicine, bioinformatics and genetic engineering. This will enable us to advance our current understanding of human-microbiota interaction in NAFLD and to develop new diagnostic and therapeutic tools to tackle NAFLD.
Our research is divided into four research work packages (WP) spanning following disciplines (I) Metabolism & Endocrinology, (II) Physiology & Biochemistry, (III) Computational & Systemsbiology, and (IV) Microbiology & Bioengioneering each one is led by a BestTreat consortium member with a world class scientific record in the field:
The active participation of end-users in our consortium (ChH, Gubra, Afekta, CliM) ensures that the project remains aligned to industry needs and regulatory frameworks for biotherapeutics. To complement the research programme we offer a bespoke training series. We get support from technology assessment and communication leaders (Biofaction, CSBJ, DK4),
Our research is divided into four research work packages (WP) spanning following disciplines (I) Metabolism & Endocrinology, (II) Physiology & Biochemistry, (III) Computational & Systemsbiology, and (IV) Microbiology & Bioengioneering each one is led by a BestTreat consortium member with a world class scientific record in the field:
- WP 2: Human Cohorts & Mice Model: Discover associations and the predictive role of the gut microbiota and exercise onto NAFLD
- WP 3: Mechanistic Studies of Microbiome-Host Interaction: Discover serum biomarkers and exercise responsive microbiota relevant for prognosis of NAFLD
- WP 4: Big Data Analysis of the Gut Microbiota: Model the associations between microbial community parameters and NAFLD progression state by integrating meta-omics datasets
- WP 5: Phenotyping, Engineering & Characterisation: Identify, characterise and culture strains for microbiome therapeutics. Validate best strains in vivo and ex vivo
The active participation of end-users in our consortium (ChH, Gubra, Afekta, CliM) ensures that the project remains aligned to industry needs and regulatory frameworks for biotherapeutics. To complement the research programme we offer a bespoke training series. We get support from technology assessment and communication leaders (Biofaction, CSBJ, DK4),